Deferiprone

Overview

Deferiprone is an oral iron chelator used to treat iron overload in patients with transfusion-dependent thalassemia. It forms a stable complex with trivalent iron (Fe3+) and is then eliminated from the body, reducing iron levels and preventing organ damage.

API suppliers (7)

Suppliers of Deferiprone evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• Taro Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
• Apotex Inc.Canada1 active DMF
• Emcure Pharmaceuticals LimitedIndia1 active DMF GMP on record
• AARTI PHARMALABS LIMITEDIndia1 active DMF
• INDUSTRIALE CHIMICA SRLItaly1 active DMF GMP on record
• Cadila Healthcare LimitedIndia
• KATWIJK CHEMIE BVNetherlandsCEP GMP on record

EU CEP holders (1)

Companies holding a valid EU Certificate of Suitability (CEP) for Deferiprone, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (9 approved US products), the latest listed US patent on Deferiprone expires 25 Oct 2038 and exclusivity 30 Apr 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas